We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Multitiered Molecular Control Mechanism Regulates T-cell Genetic Switch

By LabMedica International staff writers
Posted on 27 Jul 2016
Three distinct molecular processes act in a stage-specific manner to provide a multitiered system for regulating the T-cell developmental gene BCL11B (B-cell CLL/Lymphoma 11B).

During T-cell development, multipotent progenitors commit to the T-cell lineage by turning on the BCL11B gene, which encodes a transcription factor. More...
To identify the factors responsible for controlling the commitment mechanism, investigators at the California Institute of Technology (Pasadena, USA) followed developing T-cells at the single-cell level using mice genetically engineered to express a fluorescent protein in addition to their own Bcl11b protein. This caused the mouse cells to glow under the fluorescent microscope when the BCL11B gene was activated.

Results published in the July 4, 2016, online edition of the journal Nature Immunology revealed that a group of four protein transcription factors cooperated in a series of multi-tiered steps to regulate the T-cell genetic switch.

Initially, the proteins HNF1 homeobox A (HNF1A; also known as TCF1) and GATA binding protein 3 (GATA3) performed an early locus "poising" function, which paved the way for the activation step. Next, Notch protein signaling activated BCL11B. The fourth protein, Runt-related transcription factor 1 (Runx1) controlled the amplitude of the signal.

"We identify the contributions of four regulators of BCL11B, which are all needed for its activation but carry out surprisingly different functions in enabling the gene to be turned on," said senior author Dr. Ellen Rothenberg, professor of biology at the California Institute of Technology. "It is interesting - the gene still needs the full quorum of transcription factors, but we now find that it also needs them to work in the right order. This makes the gene respond not only to the cell's current state, but also to the cell's recent developmental history."

Related Links:
California Institute of Technology



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Immunofluorescence Analyzer
IFA System
Chromogenic Culture System
InTray™ COLOREX™ ECC
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Graphical abstract (Pola, I., Akinyemi, T., Tan, K. et al. Nature Communications(2026). https://doi.org/10.1038/s41467-026-74971-4)

Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease

Blood-based biomarkers are emerging as tools for detecting Alzheimer’s disease–related changes without relying on advanced brain imaging or cerebrospinal fluid (CSF) analysis. However, much of the foundational... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.